Poseida Therapeutics, Inc. is seeking an outstanding candidate to join our immuno-oncology team at La Jolla, San Diego, CA.  The T Cell Engineering Research Scientist will have a PhD or equivalent in cellular biology, molecular biology, Immunology, or related field and ≥ 2 years of experience.  The Scientist will have demonstrated expertise in the genetic manipulation of primary T cells and/or laboratory human cell lines using the latest gene editing tools (CRISPRs, TALENs and/or ZFNs), as well as the generation of lines with stable gene integrations (using viral transduction, transposon system, or other).  Prior experience designing and utilizing multicistronic vectors is a plus.  The Scientist will plan and perform experiments for the development and evaluation of primary human T cell KOs and engineered human cell lines.  The successful candidate will demonstrate excellent oral and written communication skills, work well independently and as part of a team, and be able to work on multiple projects simultaneously.  Broad expertise cellular biology, molecular biology, and flow cytometry is required for this role.  The position is a hands-on, laboratory-based role with the possibility of direct reports.

Poseida is currently developing CAR-T and gene therapy products for cancer and orphan diseases.  Poseida is a pre-IPO company with $30M in Series A financing and is currently partnered with J&J’s Janssen to develop allogeneic CAR-T therapies against cancer.  Poseida has entered into a worldwide License Agreement with Janssen to research, develop, manufacture and commercialize licensed products using Janssen Centyrin technology.  Centyrins are non-scFv, alternative binders that are fully human and one fifth the size of a traditional scFv.  Poseida boasts best-in-class genome engineering capabilities for stable transgene integration or targeted gene disruption.  Proprietary tools include piggyBac™ DNA Modification System (capable of delivering 300kb+ of cargo for stable integration and long-term expression), Footprint-Free™ Gene Editing System, NextGEN™ CRISPR, and XTN™ TALEN, which are synthetic, non-viral, and can be surgically precise.  Poseida aims to advance the first CAR-T product against multiple myeloma Phase I clinical trials in 2017.  Please visit for more information.

Required Experience and Skills:

  • PhD or equivalent in cellular biology, molecular biology, Immunology, or related field and ≥ 2 years of experience in the field
  • Expertise in the characterization, culture, expansion, and manipulation of primary T cells and laboratory cell lines
  • Genetic manipulation using CRISPRs, TALENs, and/or ZFNs
  • Stable gene knock-ins using viral transduction, transposon-based systems, or other
  • Molecular biology, Cloning and PCR technologies, genetic manipulation
  • Vector design, especially multicistronic DNA vectors
  • Electroporation techniques and technologies (Plasmid DNA, IVT RNA)
  • Multi-parameter flow cytometry and proficiency in FACS data analysis programs
  • Cell separation technologies (e.g., Miltenyi AutoMACS) and FACS sorting
  • Ability to organize, communicate, and present complex data sets to key stakeholders from diverse backgrounds
  • Excellent oral and communication skills

Preferred Experience and Skills:

  • A detailed knowledge of cellular and/or tumor immunology principles, technologies, and experimental techniques (cell culture, in vitro cellular assays, flow cytometry, etc…)
  • Functional assays measuring cellular activation, cytokine release, proliferation, and killing
  • Demonstrated track record in successfully developing and employing in vitro/in vivo models
  • Strong understanding of transplantation biology and the role of histocompatibility antigens
  • Murine tumor models (genetically engineered or syngeneic)
  • Work with external academic, biotechnology, and contract research organizations
  • Mentor and guide other scientists in the group as needed
  • Previous supervisory skills